Compendial Globalization: Achieving Harmonization through Standardized Practices and Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compendial Globalization: Achieving Harmonization through Standardized Practices and Collaboration
The authors discuss a new approach to address globally harmonized compendial standards.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 94-101

Regulatory acceptance

The third principle of compendial globalization is not focused on the pharmacopeias, but rather on the regulatory agencies. Compendial globalization can only succeed if the regulators are willing to accept the outcomes based upon the standardized pharmacopeial practices and pharmacopeial collaboration. Having harmonized compendial processes and interchangeable standards will aid in the regulators' efforts to ensure the quality of medicines, in light of the challenges created by the increasingly complex global supply chain.

Acceptance of compendial globalization by the regulatory agencies will be facilitated by their participation in the development of the underlying principles of standardized pharmacopeial practices and pharmacopeial collaboration. The existing framework for regulatory review and comment on compendial standards (monographs and general chapters) provides further assurance of appropriate quality for drug products and ingredients. It is envisioned that harmonized and interchangeable compendial standards could help to harmonize compendial information in regulatory submissions, reducing the number of postapproval changes submitted by industry, thereby removing the need for this additional review and approval by health authorities. Regulatory acceptance of the outcomes of compendial globalization will also provide a baseline for the regulatory expectations for compendial testing that are reviewed during inspections. These aspects will ultimately provide consistent quality medicines for global patients without an additional regulatory burden.

Benefits of compendial globalization

The ultimate beneficiaries of compendial globalization are patients worldwide through the increased availability of affordable medicines with appropriate, consistent, and globally applicable quality standards. This benefit is achieved through the harmonized compendial requirements which facilitate drug development, specification setting, global drug product registrations, and inspection of facilities. Additional benefits come from the simplification of the supply chain and quality assurance processes for global medicines.


Figure 2: Current state of monograph development.
Another practical benefit is the improved utilization of resources by global stakeholders (i.e., industry, pharmacopeias, and regulators) who are directly impacted by compendial standards. This benefit is achieved by eliminating redundancies in industry, pharmacopeial, and regulatory processes. For the pharmaceutical industry, there is direct benefit in harmonized quality requirements which eliminate redundant testing that provides no additional benefit to the patient. Both the industry and pharmacopeias also benefit from simplification of processes for developing compendial standards (see Figures 2 and 3).


Figure 3: Proposed state of monograph development.
The current process for developing a new monograph for a single drug substance or product (see Figure 2) requires parallel and redundant work activities. A company may develop and submit multiple proposals to several different pharmacopeias. Each pharmacopeia then follows the steps of its own process for monograph elaboration, typically resulting in different outcomes that are published for review and comment in pharmacopeial forums. The company must monitor each of the respective forums, and respond to the different drafts. Once the pharmacopeias take account of the comments from all impacted stakeholders, including those from other companies and regulatory agencies, the different monographs are published as official. All impacted companies must then complete appropriate change control to their testing standards, as needed, to ensure compliance with the disharmonized monograph requirements.

The work for all stakeholders is simplified by compendial globalization (see Figure 3), where a harmonized monograph results from a single submission by the company. Using the standardized practices and collaboration, one pharmacopeia is able to develop the harmonized monograph and other pharmacopeias are able to adopt this standard, based on collaboration between the pharmacopeias and with the submitter of the monograph. This frees up resources for the other pharmacopeias, enabling them to develop other standards, rather than duplicating the effort for the first monograph. The resulting harmonized compendial standards reduce the complexity of regulatory review of registrations and inspection of facilities. One globally applicable quality standard would exist, regardless of which pharmacopeia might be referenced in a registration or used for release testing. These outcomes provide global patient benefit and make the pursuit of compendial globalization a worthwhile effort.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here